ABBV AbbVie
AbbVie earnings company data as of 3:00 PM ET 10/23
- 1 of 1 EPS beats
- 3 Owners
- Rank #81
- Max 0.7%
- Master 0.01%
History
2 periods, newest first. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 30 Oct | EPS | 3.74 | — | — |
| Rev | $17.36B | — | — | ||
| FY2026 Q2 | 31 Jul | EPS | 3.60 | 3.65 | Beat +1.4% |
| Rev | $16.78B | $16.99B | Beat +1.2% |
Who owns this now
Largest portfolio weights among holders, up to 0.7% (David Katz, Matrix Asset Advisors). Not free-float ownership.
Insider trades
Open-market buys and sales by ABBV's executives, directors and 10% owners in the last 12 months, from their Form 4s
- None no insider bought on the open market
- $8.2M sold by 1 insider outside a trading plan
- None no planned (10b5-1) sales
-
Nicholas Donoghoe EVP, Chief Bus/Strat OfficerSale$8.2M 32,710 shares at $250.00 31% of stakeTraded Aug 14 Filed Aug 18
Also filed in the last 12 months, not counted as buying or selling: 11 stock grants and 1 option exercise.
SEC filings
Recent issuer filings from EDGAR, 19 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| 8-K | 5.02 | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 8-K | 7.01,9.01 | Filing Doc | |
| 8-K | 8.01,9.01 | Filing Doc | |
| 424B5 | Filing Doc | ||
| 8-K | 8.01,9.01 | Filing Doc | |
| 424B5 | Filing Doc | ||
| 10-Q | Filing Doc | ||
| 8-K | 2.02,9.01 | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 8-K | 7.01,9.01 | Filing Doc | |
| 8-K | 5.07 | Filing Doc | |
| 10-Q | Filing Doc | ||
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| DEF 14A | Filing Doc | ||
| DEFA14A | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.